Logo image of NEO

NEOGENOMICS INC (NEO) Stock Fundamental Analysis

NASDAQ:NEO - Nasdaq - US64049M2098 - Common Stock - Currency: USD

5.16  +0.32 (+6.61%)

After market: 5.06 -0.1 (-1.94%)

Fundamental Rating

4

Overall NEO gets a fundamental rating of 4 out of 10. We evaluated NEO against 103 industry peers in the Health Care Providers & Services industry. The financial health of NEO is average, but there are quite some concerns on its profitability. NEO is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NEO had positive earnings in the past year.
In the past year NEO had a positive cash flow from operations.
NEO had negative earnings in 4 of the past 5 years.
In multiple years NEO reported negative operating cash flow during the last 5 years.
NEO Yearly Net Income VS EBIT VS OCF VS FCFNEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

NEO's Return On Assets of -7.46% is on the low side compared to the rest of the industry. NEO is outperformed by 74.76% of its industry peers.
Looking at the Return On Equity, with a value of -12.18%, NEO is doing worse than 63.11% of the companies in the same industry.
Industry RankSector Rank
ROA -7.46%
ROE -12.18%
ROIC N/A
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
NEO Yearly ROA, ROE, ROICNEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15

1.3 Margins

NEO has a Gross Margin of 43.91%. This is in the better half of the industry: NEO outperforms 72.82% of its industry peers.
NEO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
NEO Yearly Profit, Operating, Gross MarginsNEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

4

2. Health

2.1 Basic Checks

NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEO has more shares outstanding
NEO has more shares outstanding than it did 5 years ago.
NEO has a worse debt/assets ratio than last year.
NEO Yearly Shares OutstandingNEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NEO Yearly Total Debt VS Total AssetsNEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.87, we must say that NEO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.87, NEO is not doing good in the industry: 71.84% of the companies in the same industry are doing better.
NEO has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NEO (0.40) is better than 61.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z 0.87
ROIC/WACCN/A
WACC6.18%
NEO Yearly LT Debt VS Equity VS FCFNEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

NEO has a Current Ratio of 3.92. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a better Current ratio (3.92) than 91.26% of its industry peers.
NEO has a Quick Ratio of 3.58. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a Quick ratio of 3.58. This is amongst the best in the industry. NEO outperforms 90.29% of its industry peers.
Industry RankSector Rank
Current Ratio 3.92
Quick Ratio 3.58
NEO Yearly Current Assets VS Current LiabilitesNEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

NEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 200.00%, which is quite impressive.
The earnings per share for NEO have been decreasing by -20.25% on average. This is quite bad
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.69%.
Measured over the past years, NEO shows a quite strong growth in Revenue. The Revenue has been growing by 10.07% on average per year.
EPS 1Y (TTM)200%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%0%
Revenue 1Y (TTM)9.69%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%10.23%

3.2 Future

The Earnings Per Share is expected to grow by 51.11% on average over the next years. This is a very strong growth
NEO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.61% yearly.
EPS Next Y60.34%
EPS Next 2Y74.09%
EPS Next 3Y72.11%
EPS Next 5Y51.11%
Revenue Next Year12.47%
Revenue Next 2Y11.91%
Revenue Next 3Y11.38%
Revenue Next 5Y11.61%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NEO Yearly Revenue VS EstimatesNEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NEO Yearly EPS VS EstimatesNEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 43.00 indicates a quite expensive valuation of NEO.
Compared to the rest of the industry, the Price/Earnings ratio of NEO is on the same level as its industry peers.
When comparing the Price/Earnings ratio of NEO to the average of the S&P500 Index (26.82), we can say NEO is valued expensively.
The Price/Forward Earnings ratio is 17.03, which indicates a rather expensive current valuation of NEO.
Based on the Price/Forward Earnings ratio, NEO is valued a bit cheaper than 63.11% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.21. NEO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 43
Fwd PE 17.03
NEO Price Earnings VS Forward Price EarningsNEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEO Per share dataNEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NEO's earnings are expected to grow with 72.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.71
PEG (5Y)N/A
EPS Next 2Y74.09%
EPS Next 3Y72.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEOGENOMICS INC

NASDAQ:NEO (8/1/2025, 8:00:02 PM)

After market: 5.06 -0.1 (-1.94%)

5.16

+0.32 (+6.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)11-03 2025-11-03/amc
Inst Owners100.43%
Inst Owner Change0.11%
Ins Owners1.09%
Ins Owner Change3.42%
Market Cap666.57M
Analysts76.84
Price Target11.17 (116.47%)
Short Float %3.36%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.8%
Min EPS beat(2)31.6%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)116.23%
Min EPS beat(4)31.6%
Max EPS beat(4)298.27%
EPS beat(8)8
Avg EPS beat(8)214.41%
EPS beat(12)12
Avg EPS beat(12)159.12%
EPS beat(16)16
Avg EPS beat(16)122.94%
Revenue beat(2)0
Avg Revenue beat(2)-2.21%
Min Revenue beat(2)-2.68%
Max Revenue beat(2)-1.73%
Revenue beat(4)0
Avg Revenue beat(4)-1.65%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)-0.51%
Revenue beat(8)4
Avg Revenue beat(8)0.55%
Revenue beat(12)8
Avg Revenue beat(12)2.36%
Revenue beat(16)9
Avg Revenue beat(16)1.45%
PT rev (1m)0%
PT rev (3m)-39.7%
EPS NQ rev (1m)-26.87%
EPS NQ rev (3m)-34.76%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-11.94%
Revenue NQ rev (1m)-3.53%
Revenue NQ rev (3m)-1.37%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)0.69%
Valuation
Industry RankSector Rank
PE 43
Fwd PE 17.03
P/S 0.97
P/FCF N/A
P/OCF 47.45
P/B 0.78
P/tB 23.72
EV/EBITDA N/A
EPS(TTM)0.12
EY2.33%
EPS(NY)0.3
Fwd EY5.87%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.11
OCFY2.11%
SpS5.34
BVpS6.61
TBVpS0.22
PEG (NY)0.71
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.46%
ROE -12.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.91%
FCFM N/A
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.68%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.92
Quick Ratio 3.58
Altman-Z 0.87
F-Score5
WACC6.18%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)200%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%0%
EPS Next Y60.34%
EPS Next 2Y74.09%
EPS Next 3Y72.11%
EPS Next 5Y51.11%
Revenue 1Y (TTM)9.69%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%10.23%
Revenue Next Year12.47%
Revenue Next 2Y11.91%
Revenue Next 3Y11.38%
Revenue Next 5Y11.61%
EBIT growth 1Y-4.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year159.59%
EBIT Next 3Y46.57%
EBIT Next 5Y31.13%
FCF growth 1Y70.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y141.09%
OCF growth 3YN/A
OCF growth 5Y-21.37%